Formononetin inhibits p53 signaling pathway activation to delay cellular senescence and ameliorates diabetic kidney disease

doi:10.4239/wjd.v17.i2.112500

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

(41)

(54)

(0)

(14)

(666)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. Feb 15, 2026; 17(2): 112500
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112500

Full Size Figure Download Figure

Figure 9 Formononetin delays cellular senescence in diabetic kidney disease by inhibiting hyperactivation of the p53 signaling pathway. DKD: Diabetic kidney disease.

Citation: Ji Y, Liu RX, He PY, Zhou YM, Li YC, Guo J, Nie B, Liu YN, Liu WJ. Formononetin inhibits p53 signaling pathway activation to delay cellular senescence and ameliorates diabetic kidney disease. World J Diabetes 2026; 17(2): 112500
URL: https://www.wjgnet.com/1948-9358/full/v17/i2/112500.htm
DOI: https://dx.doi.org/10.4239/wjd.v17.i2.112500

Ji Y, Liu RX, He PY, Zhou YM, Li YC, Guo J, Nie B, Liu YN, Liu WJ. Formononetin inhibits p53 signaling pathway activation to delay cellular senescence and ameliorates diabetic kidney disease. World J Diabetes 2026; 17(2): 112500 [PMID: 41696102 DOI: 10.4239/wjd.v17.i2.112500]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.